Tiagabine

Last updated
Tiagabine
Tiagabine.svg
Clinical data
Pronunciation /tˈæɡəbn/
Trade names Gabitril
AHFS/Drugs.com Monograph
MedlinePlus a698014
Pregnancy
category
  • AU: B3
  • US: C (Risk not ruled out)
    Routes of
    administration
    Oral (tablets)
    ATC code
    Legal status
    Legal status
    Pharmacokinetic data
    Bioavailability 90–95% [1]
    Protein binding 96% [1]
    Metabolism Hepatic (CYP450 system, [1] primarily CYP3A) [2]
    Onset of action Tmax = 45 min [2]
    Elimination half-life 5–8 hours [3]
    Excretion Fecal (63%) and renal (25%) [2]
    Identifiers
    CAS Number
    PubChem CID
    IUPHAR/BPS
    DrugBank
    ChemSpider
    UNII
    KEGG
    ChEBI
    ChEMBL
    CompTox Dashboard (EPA)
    Chemical and physical data
    Formula C20H25NO2S2
    Molar mass 375.55 g·mol−1
    3D model (JSmol)
       (verify)

    Tiagabine (trade name Gabitril) is an anticonvulsant medication produced by Cephalon that is used in the treatment of epilepsy. The drug is also used off-label in the treatment of anxiety disorders and panic disorder.

    Contents

    Medical uses

    Tiagabine is approved by U.S. Food and Drug Administration (FDA) as an adjunctive treatment for partial seizures in individuals of age 12 and up. It may also be prescribed off-label by physicians to treat anxiety disorders and panic disorder as well as neuropathic pain (including fibromyalgia). For anxiety and neuropathic pain, tiagabine is used primarily to augment other treatments. Tiagabine may be used alongside selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, or benzodiazepines for anxiety, or antidepressants, gabapentin, other anticonvulsants, or opioids for neuropathic pain. [4]

    Side effects

    The most common side effect of tiagabine is dizziness. [5] Other side effects that have been observed with a rate of statistical significance relative to placebo include asthenia, somnolence, nervousness, memory impairment, tremor, headache, diarrhea, and depression. [5] [6] Adverse effects such as confusion, aphasia (difficulty speaking clearly)/stuttering, and paresthesia (a tingling sensation in the body's extremities, particularly the hands and fingers) may occur at higher dosages of the drug (e.g., over 8 mg/day). [5] Tiagabine may induce seizures in those without epilepsy, particularly if they are taking another drug which lowers the seizure threshold. [4] There may be an increased risk of psychosis with tiagabine treatment, although data is mixed and inconclusive. [1] [7] Tiagabine can also reportedly interfere with visual color perception. [1]

    Overdose

    Tiagabine overdose can produce neurological symptoms such as lethargy, single or multiple seizures, status epilepticus, coma, confusion, agitation, tremors, dizziness, dystonias/abnormal posturing, and hallucinations, as well as respiratory depression, tachycardia, hypertension, and hypotension. [8] Overdose may be fatal especially if the victim presents with severe respiratory depression and/or unresponsiveness. [8]

    Pharmacology

    Tiagabine increases the level of γ-aminobutyric acid (GABA), the major inhibitory neurotransmitter in the central nervous system, by blocking the GABA transporter 1 (GAT-1), and hence is classified as a GABA reuptake inhibitor (GRI). [3] [9]

    History

    Tiagabine was discovered at Novo Nordisk in Denmark in 1988 by a team of medicinal chemists and pharmacologists under the general direction of Claus Bræstrup. [10] The drug was co-developed with Abbott Laboratories, in a 40/60 cost sharing deal, with Abbott paying a premium for licensing the IP from the Danish company.[ citation needed ]

    Abbott did initially embrace the drug enthusiastically after its U.S. launch in 1998, and provided further clinical studies with the goal of gaining FDA approval for monotherapy in epilepsy. However, the senior management at Abbott drew back after realizing that the original deal with Novo would limit the company's financial gain from a monotherapy approval. After a period of co-promotion, Cephalon licensed tiagabine from Abbott/Novo and now is the exclusive producer.[ citation needed ]

    U.S. patents on tiagabine listed in the Orange Book expired in April 2016. [11]

    See also

    [12]

    Related Research Articles

    An anxiolytic is a medication, or other intervention, that inhibits anxiety. This effect is in contrast to anxiogenic agents, which increase anxiety. Together these categories of psychoactive compounds or interventions may be referred to as anxiotropic compounds or agents. Some recreational drugs such as alcohol induce anxiolysis initially; however, studies show that many of these drugs are anxiogenic. Anxiolytic medications have been used for the treatment of anxiety disorder and its related psychological and physical symptoms. Light therapy and other interventions have also been found to have an anxiolytic effect.

    Tricyclic antidepressant chemical compounds used primarily as antidepressants

    Tricyclic antidepressants (TCAs) are a class of medications that are used primarily as antidepressants. TCAs were discovered in the early 1950s and were marketed later in the decade. They are named after their chemical structure, which contains three rings of atoms. Tetracyclic antidepressants (TeCAs), which contain four rings of atoms, are a closely related group of antidepressant compounds.

    Sertraline Antidepressant medication

    Sertraline, sold under the brand name Zoloft among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is used to treat major depressive disorder, obsessive–compulsive disorder, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder, and social anxiety disorder. Sertraline is taken by mouth.

    Anticonvulsants are a diverse group of pharmacological agents used in the treatment of epileptic seizures. Anticonvulsants are also increasingly being used in the treatment of bipolar disorder and borderline personality disorder, since many seem to act as mood stabilizers, and for the treatment of neuropathic pain. Anticonvulsants suppress the excessive rapid firing of neurons during seizures. Anticonvulsants also prevent the spread of the seizure within the brain.

    Topiramate an anticonvulsant (antiepilepsy) drug

    Topiramate, sold under the brand name Topamax among others, is a medication used to treat epilepsy and prevent migraines. It has also been used in alcohol dependence. For epilepsy this includes treatment for generalized or focal seizures. It is taken by mouth.

    Lamotrigine an anticonvulsant drug used in the treatment of epilepsy and bipolar disorder

    Lamotrigine, sold as the brand name Lamictal among others, is an anticonvulsant medication used to treat epilepsy and bipolar disorder. For epilepsy, this includes focal seizures, tonic-clonic seizures, and seizures in Lennox-Gastaut syndrome. In bipolar disorder, it is used to treat acute episodes of depression and rapid cycling in bipolar type II and to prevent recurrence in bipolar type I.

    Levetiracetam Medication

    Levetiracetam, marketed under the trade name Keppra among others, is a medication used to treat epilepsy. It is used for partial onset, myoclonic, or tonic-clonic seizures. It is taken by mouth as an immediate or extended release formulation or by injection into a vein.

    Clonazepam chemical compound

    Clonazepam, sold under the brand Klonopin among others, is a medication used to prevent and treat seizures, panic disorder, and the movement disorder known as akathisia. It is a tranquilizer of the benzodiazepine class. It is taken by mouth. Effects begin within one hour and last between six and twelve hours.

    Viloxazine chemical compound

    Viloxazine is a morpholine derivative and is a selective norepinephrine reuptake inhibitor (NRI). It was used as an antidepressant in some European countries, and produced a stimulant effect that is similar to the amphetamines, except without any signs of dependence. It was discovered and brought to market in 1976 by Imperial Chemical Industries and was withdrawn from the market in the early 2000s for business reasons.

    Clobazam Benzodiazepine class medication

    Clobazam is a benzodiazepine class medication that was patented in 1968. Clobazam was first synthesized in 1966 and first published in 1969. Clobazam was originally marketed as an anxioselective anxiolytic since 1970 and an anticonvulsant since 1984. The primary drug-development goal was to provide greater anxiolytic, anti-obsessive efficacy with fewer benzodiazepine-related side effects.

    Zonisamide chemical compound

    Zonisamide is a medication used to treat the symptoms of epilepsy and Parkinson's disease. Chemically it is a sulfonamide. It serves as an anticonvulsant used primarily as an adjunctive therapy in adults with Parkinson's disease, partial-onset seizures; infantile spasm, mixed seizure types of Lennox–Gastaut syndrome, myoclonic and generalized tonic clonic seizure. Despite this it is also sometimes used as a monotherapy for partial-onset seizures.

    Stiripentol anticonvulsant medication

    Stiripentol is an anticonvulsant drug used in the treatment of epilepsy. It is approved for the treatment of Dravet syndrome, an epilepsy syndrome. It is unrelated to other anticonvulsants and belongs to the group of aromatic allylic alcohols.

    Sultiame chemical compound

    Sultiame, also known as sulthiame, is a sulfonamide and inhibitor of the enzyme carbonic anhydrase. It is used as an anticonvulsant.

    DMCM chemical compound

    DMCM (methyl-6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate) is a drug from the beta-carboline family. It acts as a negative allosteric modulator of GABAA receptors, meaning that it causes the opposite effects to the benzodiazepine class of drugs. As such, DMCM has anxiogenic and convulsant properties, and is used in scientific research to induce anxiety so that new anxiolytic medications can be tested, and to produce convulsions so that anticonvulsant medications can be tested. It has also been shown to produce analgesic effects in animals, thought to be because it produces panic which reduces the perception of pain.

    Lacosamide an anticonvulsant

    Lacosamide, sold under the brand name Vimpat among others, is a medication used in the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain. It is used by mouth or intravenously.

    Reuptake inhibitor

    A reuptake inhibitor (RI) is a type of drug known as a reuptake modulator that inhibits the plasmalemmal transporter-mediated reuptake of a neurotransmitter from the synapse into the pre-synaptic neuron. This leads to an increase in extracellular concentrations of the neurotransmitter and an increase in neurotransmission. Various drugs exert their psychological and physiological effects through reuptake inhibition, including many antidepressants and psychostimulants.

    Ganaxolone chemical compound

    Ganaxolone is an experimental drug which is under development by Marinus Pharmaceuticals for potential medical use as an anxiolytic and anticonvulsant. Ganaxolone has been shown to protect against seizures in animal models, and to act a positive allosteric modulator of the GABAA receptor.

    GABA reuptake inhibitor

    A GABA reuptake inhibitor (GRI) is a type of drug which acts as a reuptake inhibitor for the neurotransmitter gamma-Aminobutyric acid (GABA) by blocking the action of the gamma-Aminobutyric acid transporters (GATs). This in turn leads to increased extracellular concentrations of GABA and therefore an increase in GABAergic neurotransmission.

    Selective serotonin reuptake inhibitor class of antidepressant medication

    Selective serotonin reuptake inhibitors (SSRIs) are a class of drugs that are typically used as antidepressants in the treatment of major depressive disorder, anxiety disorders and related illnesses to serotonin deficiencies.

    References

    1. 1 2 3 4 5 Thomas L. Lemke; David A. Williams (24 January 2012). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. pp. 562–. ISBN   978-1-60913-345-0.
    2. 1 2 3 "Gabitril (tiagabine hydrochloride) Tablets. U.S. Full Prescribing Information" (PDF). Cephalon, Inc. Retrieved 8 April 2016.
    3. 1 2 Brodie, Martin J. (1995). "Tiagabine Pharmacology in Profile". Epilepsia. 36 (s6): S7–S9. doi:10.1111/j.1528-1157.1995.tb06015.x. ISSN   0013-9580. PMID   8595791.
    4. 1 2 Stahl, S. Stahl's Essential Psychopharmacology: Prescriber's Guide. Cambridge University Press: New York, NY. 2009. pp. 523-526
    5. 1 2 3 Leppik, Ilo E. (1995). "Tiagabine: The Safety Landscape". Epilepsia. 36 (s6): S10–S13. doi:10.1111/j.1528-1157.1995.tb06009.x. ISSN   0013-9580. PMID   8595787.
    6. M.J. Eadie; F. Vajda (6 December 2012). Antiepileptic Drugs: Pharmacology and Therapeutics. Springer Science & Business Media. pp. 459–. ISBN   978-3-642-60072-2.
    7. J. K. Aronson (2009). Meyler's Side Effects of Psychiatric Drugs. Elsevier. pp. 652–. ISBN   978-0-444-53266-4.
    8. 1 2 Spiller, Henry A.; Winter, Mark L.; Ryan, Mark; Krenzelok, Edward P.; Anderson, Debra L.; Thompson, Michael; Kumar, Suparna (2009). "Retrospective Evaluation of Tiagabine Overdose". Clinical Toxicology. 43 (7): 855–859. doi:10.1080/15563650500357529. ISSN   1556-3650. PMID   16440513.
    9. Pollack MH, Roy-Byrne PP, Van Ameringen M, Snyder H, Brown C, Ondrasik J, Rickels K (November 2005). "The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study". The Journal of Clinical Psychiatry. 66 (11): 1401–8. doi:10.4088/JCP.v66n1109. PMID   16420077.
    10. Andersen KE, Braestrup C, Grønwald FC, Jørgensen AS, Nielsen EB, Sonnewald U, Sørensen PO, Suzdak PD, Knutsen LJ (1993). "The synthesis of novel GABA uptake inhibitors. 1. Elucidation of the structure-activity studies leading to the choice of (R)-1-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]-3-piperidinecarboxylic acid (tiagabine) as an anticonvulsant drug candidate". J. Med. Chem. 36 (12): 1716–25. doi:10.1021/jm00064a005. PMID   8510100.
    11. Orange Book index page. Accessed March 22, 2016
    12. Carlson, Neil R.; Birkett, Melissa A. (2017). Physiology of Behavior (12 ed.). Psychopharmacology: Pearson. p. 103. ISBN   9780134320823.